1. EMBRACING SCIENCE. ENHANCING LIVES. Juha Yrjänheikki, PhD, CEO

2. EMBRACING SCIENCE. ENHANCING LIVES. MARKET OPPORTUNITY THE 10 BEST-SELLING DRUGS ARE MAINLY ANTIBODIES AND PROTEINS (BIOLOGICS). BIOLOGICS MARKET GROWTH 10-30% PER YEAR

3. PHARMA AND PATIENTS NEED COST-EFFECTIVE COMBINATION BIOLOGICS: MULTIPLE THERAPEUTIC PROTEINS IN ONE PRODUCT

4. EMBRACING SCIENCE. ENHANCING LIVES. THE SOLUTION – AUREALIS TECHNOLOGY Safe food-grade lactic acid bacteria producing multiple therapeutic human proteins in target tissue Lactic acid bacteria

5. EMBRACING SCIENCE. ENHANCING LIVES. AUREALIS TECHNOLOGY

6. EMBRACING SCIENCE. ENHANCING LIVES. Growth Factor in clinical use. Cytokine in clinical trials in other indications (safe and potent). Cytokine in clinical trials in other tissue repair / immune stimulation (safe and potent). Lactic acid bacteria has immune activating, anti-inflammatory and anti-infective properties. 3 4 2 1 DIABETIC FOOT ULCER (DFU) 6 BILLION USD ANNUAL MARKET AUP-16: 4

7. EMBRACING SCIENCE. ENHANCING LIVES. AUP-16 INDUCES WOUND HEALING IN DIABETIC MICE

8. EMBRACING SCIENCE. ENHANCING LIVES. AUP-552 FOR CANCER TREATMENT plasmid chromosome Factor 1 Factor 2 Factor 3 Factor 4

9. EMBRACING SCIENCE. ENHANCING LIVES. TEAM AND OFFICES Igor Mierau, PhD Director of Microbiology, Genetic Engineering and Fermentation Pia Nevalainen, BBA Management Assistant Juha Yrjänheikki, PhD CEO Thomas Wirth, PhD CSO Dirk Weber, MD, PhD CMO Haritha Samaranayake, MD, PhD Director of Inflammation and Oncology Wesley Smith, MSc. Senior Scientist CMC

10. EMBRACING SCIENCE. ENHANCING LIVES. 2019 - VISION 8/2017 - SERIES A 5/2018 - SERIES B 2016 - SEED D2013-15 SEED A-C NEED 6 + 6 = 12 MEUR RAISED 8 MEUR Private 4.0 MEUR Public 4.0 MEUR NEED 6.0 MEUR Private 3.5 MEUR Public 2.5 MEUR AUP-16 DFU Phase I/II AUP-16 VLU Phase I AUP-552 Inoperable solid tumor CTA/Phase I TARGET YEAR FUNDING PLAN AND VISION Private 10 MEUR Public 2 MEUR